BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

754 related articles for article (PubMed ID: 17477341)

  • 1. Analysis of pharmacology data and the prediction of adverse drug reactions and off-target effects from chemical structure.
    Bender A; Scheiber J; Glick M; Davies JW; Azzaoui K; Hamon J; Urban L; Whitebread S; Jenkins JL
    ChemMedChem; 2007 Jun; 2(6):861-73. PubMed ID: 17477341
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Modeling promiscuity based on in vitro safety pharmacology profiling data.
    Azzaoui K; Hamon J; Faller B; Whitebread S; Jacoby E; Bender A; Jenkins JL; Urban L
    ChemMedChem; 2007 Jun; 2(6):874-80. PubMed ID: 17492703
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predicting ADME properties and side effects: the BioPrint approach.
    Krejsa CM; Horvath D; Rogalski SL; Penzotti JE; Mao B; Barbosa F; Migeon JC
    Curr Opin Drug Discov Devel; 2003 Jul; 6(4):470-80. PubMed ID: 12951810
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Early prediction of drug metabolism and toxicity: systems biology approach and modeling.
    Bugrim A; Nikolskaya T; Nikolsky Y
    Drug Discov Today; 2004 Feb; 9(3):127-35. PubMed ID: 14960390
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Keynote review: in vitro safety pharmacology profiling: an essential tool for successful drug development.
    Whitebread S; Hamon J; Bojanic D; Urban L
    Drug Discov Today; 2005 Nov; 10(21):1421-33. PubMed ID: 16243262
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Unified QSAR approach to antimicrobials. Part 3: first multi-tasking QSAR model for input-coded prediction, structural back-projection, and complex networks clustering of antiprotozoal compounds.
    Prado-Prado FJ; González-Díaz H; de la Vega OM; Ubeira FM; Chou KC
    Bioorg Med Chem; 2008 Jun; 16(11):5871-80. PubMed ID: 18485714
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and nutritional assessment of GM plants and derived food and feed: the role of animal feeding trials.
    EFSA GMO Panel Working Group on Animal Feeding Trials
    Food Chem Toxicol; 2008 Mar; 46 Suppl 1():S2-70. PubMed ID: 18328408
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Global mapping of pharmacological space.
    Paolini GV; Shapland RH; van Hoorn WP; Mason JS; Hopkins AL
    Nat Biotechnol; 2006 Jul; 24(7):805-15. PubMed ID: 16841068
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Designing better drugs: predicting cytochrome P450 metabolism.
    de Groot MJ
    Drug Discov Today; 2006 Jul; 11(13-14):601-6. PubMed ID: 16793528
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adverse drug reactions: a review of relevant factors.
    Ajayi FO; Sun H; Perry J
    J Clin Pharmacol; 2000 Oct; 40(10):1093-101. PubMed ID: 11028248
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In silico prediction of harmful effects triggered by drugs and chemicals.
    Vedani A; Dobler M; Lill MA
    Toxicol Appl Pharmacol; 2005 Sep; 207(2 Suppl):398-407. PubMed ID: 16045954
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The challenge of predicting drug toxicity in silico.
    Vedani A; Dobler M; Lill MA
    Basic Clin Pharmacol Toxicol; 2006 Sep; 99(3):195-208. PubMed ID: 16930291
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A rational approach to maximize success rate in target discovery.
    Schneider M
    Arch Pharm (Weinheim); 2004 Dec; 337(12):625-33. PubMed ID: 15597396
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular clinical safety intelligence: a system for bridging clinically focused safety knowledge to early-stage drug discovery - the GSK experience.
    Vanderwall DE; Yuen N; Al-Ansari M; Bailey J; Fram D; Green DV; Pickett S; Vitulli G; Luengo JI; Almenoff JS
    Drug Discov Today; 2011 Aug; 16(15-16):646-53. PubMed ID: 21601652
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predicting myelosuppression of drugs from in silico models.
    Crivori P; Pennella G; Magistrelli M; Grossi P; Giusti AM
    J Chem Inf Model; 2011 Feb; 51(2):434-45. PubMed ID: 21275392
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Emerging chemical patterns: a new methodology for molecular classification and compound selection.
    Auer J; Bajorath J
    J Chem Inf Model; 2006; 46(6):2502-14. PubMed ID: 17125191
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In silico search of putative adverse drug reaction related proteins as a potential tool for facilitating drug adverse effect prediction.
    Ji ZL; Wang Y; Yu L; Han LY; Zheng CJ; Chen YZ
    Toxicol Lett; 2006 Jul; 164(2):104-12. PubMed ID: 16563668
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predicting antitrichomonal activity: a computational screening using atom-based bilinear indices and experimental proofs.
    Marrero-Ponce Y; Meneses-Marcel A; Castillo-Garit JA; Machado-Tugores Y; Escario JA; Barrio AG; Pereira DM; Nogal-Ruiz JJ; Arán VJ; Martínez-Fernández AR; Torrens F; Rotondo R; Ibarra-Velarde F; Alvarado YJ
    Bioorg Med Chem; 2006 Oct; 14(19):6502-24. PubMed ID: 16875830
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Analysis of adverse drug reactions using drug and drug target interactions and graph-based methods.
    Lin SF; Xiao KT; Huang YT; Chiu CC; Soo VW
    Artif Intell Med; 2010; 48(2-3):161-6. PubMed ID: 19962282
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In silico toxicology for the pharmaceutical sciences.
    Valerio LG
    Toxicol Appl Pharmacol; 2009 Dec; 241(3):356-70. PubMed ID: 19716836
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 38.